Jordan E Axelrad1, Michael C Sachs2, Jonas F Ludvigsson2,3,4,5, Ola Olén6,7,8. 1. Division of Gastroenterology, Department of Medicine, NYU School of Medicine, New York, New York, USA. 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 3. Department of Pediatrics, Orebro University Hospital, Orebro, Sweden. 4. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK. 5. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA. 6. Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 7. Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden. 8. Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Abstract
BACKGROUND: The Swedish Quality Register for Inflammatory Bowel Disease (SWIBREG) contains clinical data for the study of inflammatory bowel disease (IBD). The Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) cohort was recently established for the study of gastrointestinal histopathology. We aimed to develop and validate a histology score from ESPRESSO using clinical information from SWIBREG, and secondarily, to evaluate the association of the score on IBD-related hospitalization. METHODS: In a nationwide, population-based cohort study of patients with IBD during 1969-2017, we linked endoscopic inflammation in SWIBREG with histologic inflammation in ESPRESSO. We established a clinically interpretable model for predicting the endoscopic score from histology using scalable Bayesian rule lists to define a SNOMED-based histology score applicable to the ESPRESSO cohort. We also assessed the impact of baseline endoscopic and histology scores on time to IBD-related hospitalization. RESULTS: We identified 5225 individuals with IBD comprising 11,051 endoscopic assessments in SWIBREG linked to a histopathology record in ESPRESSO. We created predictive models to calculate a SNOMED-based histology score which predicted the endoscopic score. Split-sample validated areas under the ROC curves for the score predicting a non-zero endoscopic score were 0.80 (0.78-0.81) in UC, 0.70 (0.68-0.72) in CD, and 0.76 (0.73-0.78) in IBD-U. In a subset of 2741 individuals with an initial IBD diagnosis and a corresponding record in ESPRESSO with an endoscopic assessment in SWIBREG, the baseline endoscopic and histology scores were associated with time to IBD-related hospitalization (endoscopy log-rank UC p<0.001, CD p=0.020, IBD-U p<0.001; histology log-rank UC p=0.018, CD p=0.960, IBD-U p=0.034). CONCLUSION: Histopathology data in ESPRESSO accurately predict endoscopic scores in SWIBREG. Baseline endoscopic and histologic scores were associated with time to IBD-related hospitalization, particularly in UC. The SNOMED-based histology score can be used as a measure of disease activity in future register-based IBD studies.
BACKGROUND: The Swedish Quality Register for Inflammatory Bowel Disease (SWIBREG) contains clinical data for the study of inflammatory bowel disease (IBD). The Epidemiology Strengthened by histoPathology Reports in Sweden (ESPRESSO) cohort was recently established for the study of gastrointestinal histopathology. We aimed to develop and validate a histology score from ESPRESSO using clinical information from SWIBREG, and secondarily, to evaluate the association of the score on IBD-related hospitalization. METHODS: In a nationwide, population-based cohort study of patients with IBD during 1969-2017, we linked endoscopic inflammation in SWIBREG with histologic inflammation in ESPRESSO. We established a clinically interpretable model for predicting the endoscopic score from histology using scalable Bayesian rule lists to define a SNOMED-based histology score applicable to the ESPRESSO cohort. We also assessed the impact of baseline endoscopic and histology scores on time to IBD-related hospitalization. RESULTS: We identified 5225 individuals with IBD comprising 11,051 endoscopic assessments in SWIBREG linked to a histopathology record in ESPRESSO. We created predictive models to calculate a SNOMED-based histology score which predicted the endoscopic score. Split-sample validated areas under the ROC curves for the score predicting a non-zero endoscopic score were 0.80 (0.78-0.81) in UC, 0.70 (0.68-0.72) in CD, and 0.76 (0.73-0.78) in IBD-U. In a subset of 2741 individuals with an initial IBD diagnosis and a corresponding record in ESPRESSO with an endoscopic assessment in SWIBREG, the baseline endoscopic and histology scores were associated with time to IBD-related hospitalization (endoscopy log-rank UC p<0.001, CD p=0.020, IBD-U p<0.001; histology log-rank UC p=0.018, CD p=0.960, IBD-U p=0.034). CONCLUSION: Histopathology data in ESPRESSO accurately predict endoscopic scores in SWIBREG. Baseline endoscopic and histologic scores were associated with time to IBD-related hospitalization, particularly in UC. The SNOMED-based histology score can be used as a measure of disease activity in future register-based IBD studies.
Authors: Ola Olén; Rune Erichsen; Michael C Sachs; Lars Pedersen; Jonas Halfvarson; Johan Askling; Anders Ekbom; Henrik Toft Sørensen; Jonas F Ludvigsson Journal: Lancet Date: 2020-01-11 Impact factor: 79.321
Authors: Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin Journal: Clin Gastroenterol Hepatol Date: 2017-02-24 Impact factor: 11.382
Authors: Magnus Svensson; David Bergman; Ola Olén; Pär Myrelid; Johan Bohr; Anna Wickbom; Hamed Khalili; Andreas Münch; Jonas Halfvarson; Jonas F Ludvigsson Journal: Scand J Gastroenterol Date: 2019-01-02 Impact factor: 2.423
Authors: Talia Zenlea; Eric U Yee; Laura Rosenberg; Marie Boyle; Kavinderjit S Nanda; Jacqueline L Wolf; Kenneth R Falchuk; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss Journal: Am J Gastroenterol Date: 2016-03-15 Impact factor: 10.864
Authors: Sarita Shrestha; Ola Olén; Carl Eriksson; Åsa H Everhov; Pär Myrelid; Isabella Visuri; Jonas F Ludvigsson; Ida Schoultz; Scott Montgomery; Michael C Sachs; Jonas Halfvarson; Malin Olsson; Henrik Hjortswang; Jonas Bengtsson; Hans Strid; Marie Andersson; Susanna Jäghult; Michael Eberhardson; Caroline Nordenvall; Jan Björk; Ulrika L Fagerberg; Martin Rejler; Olof Grip; Pontus Karling; Mattias Block; Eva Angenete; Per M Hellström; Anders Gustavsson Journal: Scand J Gastroenterol Date: 2020-05-06 Impact factor: 2.423
Authors: Nazneen R Irani; Lai Mun Wang; Gary S Collins; Satish Keshav; Simon P L Travis Journal: J Crohns Colitis Date: 2018-11-09 Impact factor: 9.071